Real-world treatment patterns of OTX-101 ophthalmic solution, cyclosporine ophthalmic emulsion, and lifitegrast ophthalmic solution in patients with dry eye disease: a retrospective analysis.

ABSTRACT:

Background

Dry eye disease (DED) is a disorder characterized by loss of tear film homeostasis that causes ocular surface inflammation and damage. The incidence of DED increases with age. Cyclosporine ophthalmic solution 0.09% (CEQUA^®; OTX-101), cyclosporine ophthalmic emulsion 0.05% (Restasis^®; CsA), and lifitegrast ophthalmic solution 5% (Xiidra^®; LFT) are anti-inflammatory agents indicated for DED. This analysis compared treatment patterns in patients with DED receiving OTX-101, CsA, or LFT.

Methods

This real-world, retrospective, longitudinal cohort study utilized Symphony Health Integrated Dataverse claims from July 2019 to June 2021. The dataset included all patients with OTX-101 claims and patients with CsA or LFT claims randomly select

SUBMITTER: Karpecki P 

PROVIDER: S-EPMC10621228 | biostudies-literature | 2023 Nov

REPOSITORIES: biostudies-literature